GRK6 and plasma cell myeloma: In these cells, we initially performed GSIS assays in the absence or presence of a 4-aminoquinazoline derivative called compound 19, a GRK inhibitor that was developed as a potential therapeutic to target GRK6 in multiple myeloma (31, 31a).